Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress

Angiogenesis

Volumn 14, Issue 3, 2011, Pages 293-307

  Ito, Koichi ^a   Scott, Stacy A ^b   Cutler, Samuel ^a   Dong, Lan Feng ^a   Neuzil, Jiri ^a,c   Blanchard, Helen ^b   Ralph, Stephen J ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

^c INSTITUTE OF BIOTECHNOLOGY   (Czech Republic)

Author keywords

Angiogenesis; Galectin 1 inhibitor; Oxidative stress; T cell infiltration

Indexed keywords

ANTINEOPLASTIC AGENT; GALECTIN 1; HYDROGEN PEROXIDE; THIODIGALACTOSIDE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROTECTION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG SENSITIVITY; ENDOTHELIUM CELL; FEMALE; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL CELLS; FEMALE; GALECTIN 1; GENE KNOCKDOWN TECHNIQUES; IMMUNITY, CELLULAR; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE STRESS; THIOGALACTOSIDES;

MURINAE; MUS; MUS MUSCULUS;

EID: 80052755020     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-011-9213-5     Document Type: Article

References (46)

1. GA Rabinovich 2005 Galectin-1 as a potential cancer target Br J Cancer 92 7 1188 1192 10.1038/sj.bjc.6602493 15785741 10.1038/sj.bjc.6602493 1:CAS:528:DC%2BD2MXivFWltLw%3D (Pubitemid 40604390)
2. I Camby M Le Mercier F Lefranc R Kiss 2006 Galectin-1: a small protein with major functions Glycobiology 16 11 137R 157R 10.1093/glycob/cwl025 16840800 10.1093/glycob/cwl025 1:CAS:528:DC%2BD28XhtVOmurfI (Pubitemid 44530693)
3. M Le Mercier S Fortin V Mathieu I Roland S Spiegl-Kreinecker B Haibe-Kains G Bontempi C Decaestecker W Berger F Lefranc R Kiss 2009 Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression Neoplasia 11 5 485 496 19412433
4. VL Thijssen R Postel RJ Brandwijk RP Dings I Nesmelova S Satijn N Verhofstad Y Nakabeppu LG Baum J Bakkers KH Mayo F Poirier AW Griffioen 2006 Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy Proc Natl Acad Sci USA 103 43 15975 15980 10.1073/pnas.0603883103 17043243 10.1073/pnas.0603883103 1:CAS:528: DC%2BD28XhtFyltr7O (Pubitemid 44657577)
5. VL Thijssen S Hulsmans AW Griffioen 2008 The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells Am J Pathol 172 2 545 553 10.2353/ajpath.2008.070938 18202194 10.2353/ajpath.2008.070938 1:CAS:528:DC%2BD1cXis1aisL0%3D (Pubitemid 351282039)
6. XY Zhao TT Chen L Xia M Guo Y Xu F Yue Y Jiang GQ Chen KW Zhao 2010 Hypoxia inducible factor-1 mediates expression of galectin-1: the potential role in migration/invasion of colorectal cancer cells Carcinogenesis 31 8 1367 1375 10.1093/carcin/bgq116 20525878 10.1093/carcin/bgq116 1:CAS:528: DC%2BC3cXpvFWqsLw%3D
7. VL Thijssen F Poirier LG Baum AW Griffioen 2007 Galectins in the tumor endothelium: opportunities for combined cancer therapy Blood 110 8 2819 2827 10.1182/blood-2007-03-077792 17591944 10.1182/blood-2007-03-077792 1:CAS:528:DC%2BD2sXht1SmurfP (Pubitemid 350006934)
8. RO Poyton PR Castello KA Ball DK Woo N Pan 2009 Mitochondria and hypoxic signaling: a new view Ann NY Acad Sci 1177 48 56 10.1111/j.1749-6632.2009.05046. x 19845606 10.1111/j.1749-6632.2009.05046.x 1:CAS:528:DC%2BD1MXhsFWksr7N
9. AW Griffioen G Molema 2000 Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation Pharmacol Rev 52 2 237 268 10835101 1:CAS:528:DC%2BD3cXks1SksLw%3D (Pubitemid 30368433)
10. D Hanahan J Folkman 1996 Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 3 353 364 S0092-8674(00)80108- 7[pii] 8756718 10.1016/S0092-8674(00)80108-7 1:CAS:528:DyaK28XltVSks7s%3D (Pubitemid 26272076)
11. NS Brown R Bicknell 2001 Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer Breast Cancer Res 3 5 323 327 11597322 10.1186/bcr315 1:CAS:528:DC%2BD3MXntlegsLk%3D (Pubitemid 32851163)
12. K Castermans AW Griffioen 2007 Tumor blood vessels, a difficult hurdle for infiltrating leukocytes Biochim Biophys Acta 1776 2 160 174 10.1016/j.bbcan.2007.07.005 17888580 1:CAS:528:DC%2BD2sXht12hsLzN (Pubitemid 350081058)
13. J Hamzah M Jugold F Kiessling P Rigby M Manzur HH Marti T Rabie S Kaden HJ Grone GJ Hammerling B Arnold R Ganss 2008 Vascular normalization in Rgs5-deficient tumours promotes immune destruction Nature 453 7193 410 414 10.1038/nature06868 18418378 10.1038/nature06868 1:CAS:528:DC%2BD1cXlvV2qtL4%3D (Pubitemid 351693122)
14. VL Thijssen B Barkan H Shoji IM Aries V Mathieu L Deltour TM Hackeng R Kiss Y Kloog F Poirier AW Griffioen 2010 Tumor cells secrete galectin-1 to enhance endothelial cell activity Cancer Res 70 15 6216 6224 10.1158/0008-5472.CAN-09-4150 20647324 10.1158/0008-5472.CAN-09-4150 1:CAS:528:DC%2BC3cXpsVCntb8%3D
15. J He LG Baum 2006 Endothelial cell expression of galectin-1 induced by prostate cancer cells inhibits T-cell transendothelial migration Lab Invest 86 6 578 590 10.1038/labinvest.3700420 16607379 1:CAS:528:DC%2BD28Xkslemu7k%3D (Pubitemid 43780439)
16. LV Norling AL Sampaio D Cooper M Perretti 2008 Inhibitory control of endothelial galectin-1 on in vitro and in vivo lymphocyte trafficking FASEB J 22 3 682 690 10.1096/fj.07-9268com 17965266 10.1096/fj.07-9268com 1:CAS:528:DC%2BD1cXjtVaqs78%3D (Pubitemid 351348121)
17. V Mathieu M Le Mercier N De Neve S Sauvage T Gras I Roland F Lefranc R Kiss 2007 Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model J Invest Dermatol 127 10 2399 2410 10.1038/sj.jid.5700869 17495956 10.1038/sj.jid.5700869 1:CAS:528: DC%2BD2sXhtVeisb7F (Pubitemid 47619747)
18. M Le Mercier V Mathieu B Haibe-Kains G Bontempi T Mijatovic C Decaestecker R Kiss F Lefranc 2008 Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses J Neuropathol Exp Neurol 67 5 456 469 10.1097/NEN.0b013e318170f892 18431251 (Pubitemid 351653538)
19. LF Dong E Swettenham J Eliasson XF Wang M Gold Y Medunic M Stantic P Low L Prochazka PK Witting J Turanek ET Akporiaye SJ Ralph J Neuzil 2007 Vitamin E analogues inhibit angiogenesis by selective induction of apoptosis in proliferating endothelial cells: the role of oxidative stress Cancer Res 67 24 11906 11913 10.1158/0008-5472.CAN-07-3034 18089821 10.1158/0008-5472.CAN-07-3034 1:CAS:528:DC%2BD2sXhsVCjs7nJ
20. SA Scott A Bugarcic H Blanchard 2009 Characterisation of oxidized recombinant human galectin-1 Protein Pept Lett 16 10 1249 1255 19860718 10.2174/092986609789071342 1:CAS:528:DC%2BD1MXhtlentLrN
21. KA Stannard PM Collins K Ito EM Sullivan SA Scott E Gabutero I Darren Grice P Low UJ Nilsson H Leffler H Blanchard SJ Ralph 2010 Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model Cancer Lett 299 2 95 110 10.1016/j.canlet.2010.08.005 20826047 10.1016/j.canlet.2010.08.005 1:CAS:528:DC%2BC3cXhtlKhs7jM
22. Solesvik OV, Rofstad EK, Brustad T (1984) Vascular changes in a human malignant melanoma xenograft following single-dose irradiation. Radiat Res 98(1):115-128 (Pubitemid 14106046)
23. S Saussez D Glinoer G Chantrain F Pattou B Carnaille S Andre HJ Gabius G Laurent 2008 Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease Thyroid 18 7 705 712 10.1089/thy.2007.0361 18630998 10.1089/thy.2007.0361 1:CAS:528:DC%2BD1cXos1ChsLY%3D (Pubitemid 352009927)
24. S Saussez F Lorfevre T Lequeux G Laurent G Chantrain F Vertongen G Toubeau C Decaestecker R Kiss 2008 The determination of the levels of circulating galectin-1 and-3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy Oral Oncol 44 1 86 93 10.1016/j.oraloncology.2006.12.014 17350328 10.1016/j.oraloncology.2006.12.014 1:CAS:528:DC%2BD2sXhsVCjtL3I (Pubitemid 350251284)
25. D Demydenko I Berest 2009 Expression of galectin-1 in malignant tumors Exp Oncol 31 2 74 79 39/752[pii] 19550395 1:CAS:528:DC%2BD1MXhtVWitrjM
26. K Scott J Zhang 2002 Partial identification by site-directed mutagenesis of a cell growth inhibitory site on the human galectin-1 molecule BMC Cell Biol 3 3 11846886 10.1186/1471-2121-3-3 (Pubitemid 38597738)
27. K Scott C Weinberg 2004 Galectin-1: a bifunctional regulator of cellular proliferation Glycoconj J 19 7-9 467 477 10.1023/B:GLYC.0000014076.43288.89 14758070
28. S Ran A Downes PE Thorpe 2002 Increased exposure of anionic phospholipids on the surface of tumor blood vessels Cancer Res 62 21 6132 6140 12414638 1:CAS:528:DC%2BD38XosF2ms74%3D (Pubitemid 35244462)
29. QT Le G Shi H Cao DW Nelson Y Wang EY Chen S Zhao C Kong D Richardson KJ O'Byrne AJ Giaccia AC Koong 2005 Galectin-1: a link between tumor hypoxia and tumor immune privilege J Clin Oncol 23 35 8932 8941 10.1200/JCO.2005.02.0206 16219933 10.1200/JCO.2005.02.0206 1:CAS:528:DC%2BD28XktVCgtQ%3D%3D (Pubitemid 46211478)
30. WF Chiang SY Liu LY Fang CN Lin MH Wu YC Chen YL Chen YT Jin 2008 Overexpression of galectin-1 at the tumor invasion front is associated with poor prognosis in early-stage oral squamous cell carcinoma Oral Oncol 44 4 325 334 10.1016/j.oraloncology.2007.03.004 17588803 10.1016/j.oraloncology.2007.03.004 1:CAS:528:DC%2BD1cXjtl2qsLw%3D (Pubitemid 351380977)
31. I Cumpstey A Sundin H Leffler UJ Nilsson 2005 C2-symmetrical thiodigalactoside bis-benzamido derivatives as high-affinity inhibitors of galectin-3: efficient lectin inhibition through double arginine-arene interactions Angew Chem Int Ed Engl 44 32 5110 5112 10.1002/anie.200500627 16007713 10.1002/anie.200500627 1:CAS:528:DC%2BD2MXps12hsLk%3D (Pubitemid 41188556)
32. FT Liu GA Rabinovich 2005 Galectins as modulators of tumour progression Nat Rev Cancer 5 1 29 41 10.1038/nrc1527 15630413 10.1038/nrc1527 1:CAS:528:DC%2BD2MXlvVem (Pubitemid 40052323)
33. V Appay C Jandus V Voelter S Reynard SE Coupland D Rimoldi D Lienard P Guillaume AM Krieg JC Cerottini P Romero S Leyvraz N Rufer DE Speiser 2006 New generation vaccine induces effective melanoma-specific CD8 + T cells in the circulation but not in the tumor site J Immunol 177 3 1670 1678 177/3/1670[pii] 16849476 1:CAS:528:DC%2BD28XmvFCmurY%3D (Pubitemid 44092503)
34. Q Chen WC Wang SS Evans 2003 Tumor microvasculature as a barrier to antitumor immunity Cancer Immunol Immunother 52 11 670 679 10.1007/s00262-003- 0425-4 12920482 10.1007/s00262-003-0425-4 (Pubitemid 37363637)
35. AW Griffioen 2008 Anti-angiogenesis: making the tumor vulnerable to the immune system Cancer Immunol Immunother 57 10 1553 1558 10.1007/s00262-008-0524- 3 18438662 10.1007/s00262-008-0524-3 1:CAS:528:DC%2BD1cXovFyitr8%3D
36. AE Dirkx MG Oude Egbrink MJ Kuijpers ST van der Niet VV Heijnen JC Bouma-ter Steege J Wagstaff AW Griffioen 2003 Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression Cancer Res 63 9 2322 2329 12727857 1:CAS:528: DC%2BD3sXjtlGmtLY%3D (Pubitemid 36538644)
37. RK Shrimali Z Yu MR Theoret D Chinnasamy NP Restifo SA Rosenberg 2010 Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer Cancer Res 70 15 6171 6180 10.1158/0008-5472.CAN-10-0153 20631075 10.1158/0008-5472.CAN-10-0153 1:CAS:528:DC%2BC3cXpsVCntLk%3D
38. N Rubinstein M Alvarez NW Zwirner MA Toscano JM Ilarregui A Bravo J Mordoh L Fainboim OL Podhajcer GA Rabinovich 2004 Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege Cancer Cell 5 3 241 251 S1535610804000248[pii] 15050916 10.1016/S1535-6108(04)00024-8 1:CAS:528:DC%2BD2cXjtVartbY%3D (Pubitemid 38402116)
39. M Salatino DO Croci GA Bianco JM Ilarregui MA Toscano GA Rabinovich 2008 Galectin-1 as a potential therapeutic target in autoimmune disorders and cancer Expert Opin Biol Ther 8 1 45 57 10.1517/14712598.8.1.45 18081536 10.1517/14712598.8.1.45 1:CAS:528:DC%2BD2sXhsVegurvN (Pubitemid 351233722)
40. CD Chung VP Patel M Moran LA Lewis MC Miceli 2000 Galectin-1 induces partial TCR zeta-chain phosphorylation and antagonizes processive TCR signal transduction J Immunol 165 7 3722 3729 11034377 1:CAS:528:DC%2BD3cXntVyisrg%3D (Pubitemid 32057278)
41. MI Garin CC Chu D Golshayan E Cernuda-Morollon R Wait RI Lechler 2007 Galectin-1: a key effector of regulation mediated by CD4 + CD25 + T cells Blood 109 5 2058 2065 10.1182/blood-2006-04-016451 17110462 10.1182/blood-2006-04- 016451 1:CAS:528:DC%2BD2sXjtFequrw%3D (Pubitemid 46348206)
42. Y Inagaki Y Sohma H Horie R Nozawa T Kadoya 2000 Oxidized galectin-1 promotes axonal regeneration in peripheral nerves but does not possess lectin properties Eur J Biochem 267 10 2955 2964 ejb1311[pii] 10806394 10.1046/j.1432-1033.2000.01311.x 1:CAS:528:DC%2BD3cXjs1Gjs7k%3D (Pubitemid 30321342)
43. I Cumpstey E Salomonsson A Sundin H Leffler UJ Nilsson 2007 Studies of arginine-arene interactions through synthesis and evaluation of a series of galectin-binding aromatic lactose esters Chembiochem 8 12 1389 1398 10.1002/cbic.200700040 17631664 10.1002/cbic.200700040 1:CAS:528: DC%2BD2sXps1altLo%3D (Pubitemid 47300332)
44. T Delaine I Cumpstey L Ingrassia M Le Mercier P Okechukwu H Leffler R Kiss UJ Nilsson 2008 Galectin-inhibitory thiodigalactoside ester derivatives have antimigratory effects in cultured lung and prostate cancer cells J Med Chem 51 24 8109 8114 10.1021/jm801077j 19053747 10.1021/jm801077j 1:CAS:528:DC%2BD1cXhsVaht7zM
45. AW Griffioen DW van der Schaft AF Barendsz-Janson A Cox HA Struijker Boudier HF Hillen KH Mayo 2001 Anginex, a designed peptide that inhibits angiogenesis Biochem J 354 Pt 2 233 242 11171099 10.1042/0264-6021:3540233 1:CAS:528:DC%2BD3MXitFWrs70%3D (Pubitemid 32209858)
46. RP Dings DW van der Schaft B Hargittai J Haseman AW Griffioen KH Mayo 2003 Anti-tumor activity of the novel angiogenesis inhibitor anginex Cancer Lett 194 1 55 66 S0304383503000156[pii] 12706859 10.1016/S0304-3835(03)00015-6 1:CAS:528:DC%2BD3sXjtFCjsL4%3D (Pubitemid 36428885)